NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 30, 2026Sponsor estimate | NCT05870579[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerNovartis Pharmaceuticals · Breast Cancer | NVSLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT05870579[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerNovartis Pharmaceuticals · Breast CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 7, 2027Sponsor estimate | NCT04857372A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsNovartis Pharmaceuticals · Mesothelioma | NVSLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Jan 25, 2027Sponsor estimate | NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid Tumors | NVSLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 29, 2027Sponsor estimate | NCT07174063A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerNovartis Pharmaceuticals · Metastatic Prostate Cancer (mCRPC) | NVSLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT04857372A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsNovartis Pharmaceuticals · MesotheliomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2027Sponsor estimatePhase 1/Phase 2NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid TumorsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 1NCT07174063A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerNovartis Pharmaceuticals · Metastatic Prostate Cancer (mCRPC)Active, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT05552469Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesNovartis Pharmaceuticals · Myeloid Diseases | NVSLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 1NCT05552469Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesNovartis Pharmaceuticals · Myeloid DiseasesActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.